nVerses Capital’s GeneDx Holdings WGS Stock Holding History

nVerses Capital’s Portfolio WGS Stock Details WGS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-1,900	Closed	-$49.7K	–	1420
2024 Q2	$49.7K	Buy	+1,900	New	+$36K	0.03%	596

Other funds holding WGS

Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return

Corvex Management New York $3.27B AUM 38.53% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

OIM

Oracle Investment Management Greenwich, Connecticut $168M AUM 42.86% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Gagnon Securities New York $519M AUM 44.91% 1-Year Est. Return

Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Blackstone Inc New York $39B AUM 18.55% 1-Year Est. Return

nVerses Capital's WGS Position: Q3 2024 in Review

nVerses Capital sold out of GeneDx Holdings (WGS) in Q3 2024, closing a stake of 1,900 shares — an estimated $49.7K sold.

nVerses Capital first reported a position in WGS in Q2 2024 and held it in 1 quarter. The position peaked at $49.7K in Q2 2024. 136 funds tracked by Wall St. Rank hold WGS as of Q3 2024.

nVerses Capital reported no remaining GeneDx Holdings position as of Q3 2024 after selling out during the quarter.
nVerses Capital sold 1,900 GeneDx Holdings shares in Q3 2024, an estimated $49.7K.
nVerses Capital first reported a position in GeneDx Holdings in Q2 2024 and held it in 1 quarter.
nVerses Capital's GeneDx Holdings position peaked at $49.7K in Q2 2024.
136 funds tracked by Wall St. Rank held GeneDx Holdings as of Q3 2024.

Based on nVerses Capital's 13F filing for Q3 2024, filed 16 Oct 2024.